One-month therapy with simvastatin restores endothelial function in hypercholesterolemic children and adolescents

dc.contributor.authorFerreira, Waldinai Pereira
dc.contributor.authorBertolami, Marcelo Chiara
dc.contributor.authorSantos, Simone Nascimento
dc.contributor.authorBarros, Marcos Roberto A. C.
dc.contributor.authorMatos Barretto, Rodrigo Bellio de
dc.contributor.authorPontes, Rgio Cunha
dc.contributor.authorPontes, Sergio Cunha
dc.contributor.authorFonseca, Francisco Hermann
dc.contributor.authorCarvalho, Antonio Carlos
dc.contributor.institutionUniversidade Federal de São Paulo (UNIFESP)
dc.contributor.institutionInst Dante Pazzanese Cardiol
dc.date.accessioned2016-01-24T12:41:51Z
dc.date.available2016-01-24T12:41:51Z
dc.date.issued2007-02-01
dc.description.abstractSimvastatin has been shown to restore endothelial function in children with familial hypercolesterolemia after 28 weeks of treatment. the aim of this study was to evaluate 1-month simvastatin treatment effect on endothelial function in hypercholesterolemic children and adolescents. Eighteen hypercholesterolemic patients (HC group) and 18 healthy controls, aged 6-18 years, were studied with medical history, physical examination, full lipid profile, serum apolipoprotein B (apo B), fibrinogen, hepatic transaminases, and creatine kinase concentrations. Flow-mediated dilatation (FMD) was performed by high-resolution ultrasound of the brachial artery. the HC group received simvastatin 10 mg/day for 1 month. Arterial diameter was measured by two experienced sonographers who were unaware of subjects' conditions. At baseline, FMD was impaired in the HC group (mean, 5.27 +/- 4.67%) compared to controls (mean, 15.05 +/- 5.97%) (p < 0.001). After treatment, we observed a significant reduction in total cholesterol (TC) (29%), low-density lipoprotein cholesterol (LDL-C); (37%), apo B concentrations (36%) and FMD restoration (mean, 12.94 +/- 7.66%), with an absolute increase of 7.66 +/- 8.58 (p = 0.001). These results show that children and adolescents with hypercholesterolemia present endothelial dysfunction, and simvastatin, in addition to significantly reducing TC, LDL-C, and apo B concentrations, restores endothelial function with 1-month treatment.en
dc.description.affiliationUniversidade Federal de São Paulo, Cardiol Discipline, BR-04024002 São Paulo, Brazil
dc.description.affiliationInst Dante Pazzanese Cardiol, BR-04012180 São Paulo, Brazil
dc.description.affiliationUnifespUniversidade Federal de São Paulo, Cardiol Discipline, BR-04024002 São Paulo, Brazil
dc.description.sourceWeb of Science
dc.format.extent8-13
dc.identifierhttp://dx.doi.org/10.1007/s00246-005-1304-x
dc.identifier.citationPediatric Cardiology. New York: Springer, v. 28, n. 1, p. 8-13, 2007.
dc.identifier.doi10.1007/s00246-005-1304-x
dc.identifier.issn0172-0643
dc.identifier.urihttp://repositorio.unifesp.br/handle/11600/29482
dc.identifier.wosWOS:000244453100002
dc.language.isoeng
dc.publisherSpringer
dc.relation.ispartofPediatric Cardiology
dc.rightsinfo:eu-repo/semantics/restrictedAccess
dc.rights.licensehttp://www.springer.com/open+access/authors+rights?SGWID=0-176704-12-683201-0
dc.subjectcholesterolen
dc.subjecthypercholesterolemiaen
dc.subjectendotheliumen
dc.titleOne-month therapy with simvastatin restores endothelial function in hypercholesterolemic children and adolescentsen
dc.typeinfo:eu-repo/semantics/article
Arquivos
Coleções